摘要
2002年曲妥珠单抗获批上市,开启了我国乳腺癌靶向治疗的新纪元。20年来,中国乳腺癌抗人表皮生长因子受体2(HER2)治疗经历了单靶向药物、酪氨酸激酶抑制剂、双靶向药物和抗HER2联合抗体-药物偶联物等阶段;抗HER2靶向治疗格局的变化,不断改变着HER2阳性乃至HER2低表达患者的治疗模式,显著改善了患者预后。20年来,中国学者从参与国际临床试验、完成进口产品注册研究,到结合中国临床实际,开发中国自主知识产权的产品,丰富了HER2靶向治疗临床研究证据,形成了兼具国际标准与中国特色的治疗体系,《中国临床肿瘤学会乳腺癌诊疗指南》和《靶向HER2乳腺癌临床诊疗中国专家共识》的制定,更是中国智慧和中国贡献的集中体现。
Since trastuzumab was listed and approved for breast cancer in 2002,China has entered a new epoch of targeted therapy.Over the past 20 years,anti-human epidermal growth factor receptor 2(HER2)targeted therapy for breast cancer in China has experienced the era of single-target,tyrosine kinase inhibitors,double-target and anti-HER2 plus antibody-drug conjugate.Advancement in the anti-HER2 targeted therapy is continuously changing the treatment mode of patients with HER2 positive status and even HER2 low expression,significantly improved their prognosis.In the past 20 years,Chinese scholars have participated in international clinical researches,completed a series of registration studies of imported drugs,developed new drugs with proprietary intellectual property rights,enriched the evidence of clinical research on HER2-targeted therapy,and formed a treatment system with both international standards and Chinese characteristics.In particular,the formulation of the Chinese Society of Clinical Oncology Breast Cancer Guidelines and the Chinese expert consensus on anti-HER2 targeted treatment in breast cancer are the concentrated embodiments of Chinese wisdom.
作者
刘滨
李健斌
江泽飞
Liu Bin;Li Jianbin;Jiang Zefei(Department of Oncology,the Fifth Medical Center of People′s Liberation Army General Hospital,Beijing 100071,China)
出处
《中华外科杂志》
CAS
CSCD
北大核心
2023年第2期89-94,共6页
Chinese Journal of Surgery
关键词
乳腺肿瘤
抗肿瘤联合化疗方案
受体
表皮生长因子
研究进展
Breast neoplasms
Antineoplastic combined chemotherapy protocols
Receptor,epidermal growth factor
Research progress
